Overview

Heart Rate Response to Regadenoson and Sudden Cardiac Death

Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether a blunted heart rate response to regadenoson is an independent predictor of sudden cardiac death.
Phase:
N/A
Details
Lead Sponsor:
University of Alabama at Birmingham
Collaborator:
Astellas Scientific & Medical Affairs, Inc.
Treatments:
Regadenoson